Oleoyl estrone

Drug Profile

Oleoyl estrone

Alternative Names: Estrone 3-oleate; Merlin 2; MP-101; Oleoyl-estrone

Latest Information Update: 11 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Barcelona
  • Developer Manhattan Pharmaceuticals
  • Class Estrenes; Obesity therapies; Oleic acids
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 11 Jul 2007 Discontinued - Phase-II for Obesity in Switzerland (PO)
  • 11 Jul 2007 Discontinued - Phase-II for Obesity in USA (PO)
  • 10 May 2007 Manhattan Pharmaceuticals completes dosing in its phase IIa trials for obesity in the US and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top